Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer

Background: Monoclonal antibodies against PD-1 or PD-L1 have been established in clinical practice for the treatment of both early and advanced/metastatic triple-negative breast cancer. Beyond the established immune checkpoints (ICPs) (PD-1 and CTLA-4), additional ICPs, such as lymphocyte activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Heimes, Anne-Sophie, Almstedt, Katrin, Krajnak, Slavomir, Runkel, Anne, Droste, Annika, Schwab, Roxana, Stewen, Kathrin, Lebrecht, Antje, Battista, Marco J., Brenner, Walburgis, Hasenburg, Annette, Gehrmann, Mathias, Hengstler, Jan G., Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599264/
https://www.ncbi.nlm.nih.gov/pubmed/36289918
http://dx.doi.org/10.3390/biomedicines10102656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599264/
https://www.ncbi.nlm.nih.gov/pubmed/36289918
http://dx.doi.org/10.3390/biomedicines10102656

Ejemplares similares